SETDB1 and neoplasm: The use of epigenetic inhibitor such as DNMT1, EZH27, SETDB1, etc., have been reported to improve anti‐tumour immunity, by increasing the interferon response within tumour cells, upregulating the expression of antigen presenting genes, thereby transforming ‘immune cold tumours’ into ‘immune hot tumours’.6, 7